Overview
- VERVE-102’s interim Phase 1b Heart-2 results, disclosed at the European Atherosclerosis Society Congress on Monday, showed dose-related mean PCSK9 reductions of about 51% to 88% and LDL‑C falls up to 62% with effects reported through 18 months.
- Lilly reported a favorable early safety profile with no treatment‑related serious adverse events or dose‑limiting toxicities and only mild infusion reactions and fatigue; all 35 treated participants completed their assigned dose with no withdrawals.
- The therapy is a one‑time intravenous in vivo base edit that aims to permanently silence the PCSK9 gene in liver cells, reducing the enzyme that lowers LDL receptor levels and thereby lowering circulating LDL cholesterol.
- The FDA has given VERVE-102 Fast Track designation and Lilly said it plans to start a Phase 2 study by year‑end to test the finding in larger and more diverse patient groups.
- If confirmed in bigger trials the approach could replace repeat PCSK9 drugs for some high‑risk patients, but key questions remain about rare long‑term safety, off‑target editing and real‑world durability; the data also prompted a modest uptick in Lilly shares.